---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-010415"
form_type: "8-K"
ticker: "MTVA"
cik: "0001638287"
company_name: "MetaVia Inc."
filed_at: "2025-08-06T23:59:59+00:00"
generated_at: "2026-05-17T19:31:26.727287+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# MetaVia extends Phase 1 DA-1726 48mg MAD cohort to 8 weeks; top-line data Q4 2025

## Summary
- Extended 48 mg MAD cohort to 8 weeks from 4; first patient received fifth weekly dose.
- Top-line data from the extended cohort expected in Q4 2025.
- Prior 32 mg dose data: mean weight loss 4.3% by Day 26, early satiety in 83% of patients.
- Waist circumference reduction of up to 3.9 inches by Day 33 at 32 mg dose.
- DA-1726 is a dual GLP1R/GCGR agonist for obesity with a 3:1 balanced activation ratio.

## SEC filing metadata
- accession: 0001558370-25-010415
- form_type: 8-K
- ticker: MTVA
- cik: 0001638287
- company_name: MetaVia Inc.
- filed_at: 2025-08-06T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1638287/000155837025010415/0001558370-25-010415-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1638287/000155837025010415/mtva-20250806x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-010415
- JSON: https://secwatch.observer/filing/0001558370-25-010415.json
- Plain text: https://secwatch.observer/filing/0001558370-25-010415.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.